The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: A small-scale clinical study

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Ohkura, Tsuyoshi ^a   Inoue, Kazuoki ^a   Fujioka, Youhei ^a   Nakanishi, Risa ^a   Shiochi, Hideki ^a   Sumi, Keisuke ^a   Yamamoto, Naoya ^a   Matsuzawa, Kazuhiko ^a   Izawa, Shoichiro ^a   Ohkura, Hiroko ^a   Kato, Masahiko ^a   Yamamoto, Kazuhiro ^a   Taniguchi, Shin Ichi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Glinide; Meal tolerance test; Proinsulin; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; GLIMEPIRIDE; INSULIN; ISOINDOLE DERIVATIVE; MITIGLINIDE; PROINSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISOINDOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; POSTPRANDIAL PERIOD; PROINSULIN; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES;

EID: 84887350339     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-453     Document Type: Article

References (27)

1. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. DeFronzo RA, Diabetes 1988 37 667 687 10.2337/diab.37.6.667 3289989
2. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin dependent diabetes mellitus. Reder ME, Porte D Jr, Schwartz RS, et al. J Clin Endocrinol Metab 1998 83 604 608 10.1210/jc.83.2.604 9467581 (Pubitemid 28496546)
3. Intact proinsulin and β-cell function in lean and obese subjects with and without type 2 diabetes. Michael R, et al. Diabetes Care 1999 22 609 614 10.2337/diacare.22.4.609 10189540
4. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, Kunisaki M, Imamura M, Yu HY, Etoh T, Yoshikawa H, Aoki T, Hashimoto T, Nawata H, Endocr J 2000 47 763 770 10.1507/endocrj.47.763 11228051 (Pubitemid 32118490)
5. Sulfonylurea induced β-cell apoptosis in cultured human islets. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY, J Clin Endocrinol Metab 2005 90 501 506 15483097 (Pubitemid 40116700)
6. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Kadowaki T, Miyake Y, Kajinuma H, Diabetologia 1984 26 44 49 6368299 (Pubitemid 14182349)
7. Risk factors for the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japan. Kadowaki T, Yoshinaga H, Diabetes Res Clin Pract 1994 24 123 127
8. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M, Cardiovasc Diabetol 2012 11 79 10.1186/1475-2840-11-79 22748110
9. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T, Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, Diabetes Res Clin Pract 2002 55 65 85 10.1016/S0168-8227(01)00365-5 11755481 (Pubitemid 34036538)
10. The test meal A:a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. Yoshino G, Tominaga M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, Tachikawa T, J Jpn Diabetes Soc 2006 49 361 371 (Pubitemid 43973939)
11. 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi SI, Yamamoto K, Cardiovasc Diabetol 2013 12 21 10.1186/1475-2840-12-21 23339473
12. Committee on the standardization of diabetes mellitus-related laboratory testing of Japan diabetes society, "international clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycohemoglobin standardization program values. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H, J Diabetes Invest 2012 3 39 40 10.1111/j.2040-1124.2012.00207.x
13. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT, J Clin Invest 1967 46 323 335 10.1172/JCI105534 6023769
14. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825 (Pubitemid 15018832)
15. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Matsuda M, DeFronzo RA, Diabetes Care 1999 22 1462 1470 10.2337/diacare.22.9.1462 10480510 (Pubitemid 29418240)
16. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment. Kawai J, Ohara-Imaizumi M, Nakamichi Y, Okamura T, Akimoto Y, Matsushima S, Aoyagi K, Kawakami H, Watanabe T, Watada H, Kawamori R, Nagamatsu S, Biochem J 2008 412 93 101 10.1042/BJ20071282 18254725 (Pubitemid 351678339)
17. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats. Laghmich A, Ladriere L, Malaisse-Lagae F, Malaisse WJ, Pharmacol Res 1999 40 475 482 10.1006/phrs.1999.0551 10660944
18. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. Roder ME, Porte D Jr, Schwartz RS, Kahn SE, J Clin Endocrinol Metab 1997 83 604 608 (Pubitemid 28496546)
19. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A, Diabetologia 2005 48 1919 1924 10.1007/s00125-005-1849-5 16007412 (Pubitemid 41317849)
20. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. Haffner SM, Mykkänen L, Valdez RA, Stern MP, Holloway DL, Monterrosa A, Bowsher RR, J Clin Endocrinol Metab 1994 79 1806 1810 10.1210/jc.79.6.1806 7989488
21. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Forst T, Diabetes Care 2004 27 682 687 10.2337/diacare.27.3.682 14988285 (Pubitemid 38280533)
22. Effect of metformin on intact proinsulin and des 31, 32 proinsulin concentrations in subjects with non' insulin dependent (type2) diabetes mellitus. Nagi DK, Ali VM, Yudkin JS, Diabetic Med 1996 13 753 757 10.1002/(SICI)1096-9136(199608)13:8<753::AID-DIA163>3.0.CO;2-Z 8862952 (Pubitemid 26252956)
23. Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. Pfützner A, Forst T, J Diabetes Sci Technol 2011 5 784 793 21722594
24. Hyperinsulinaemia of hypertriglyceridaemia: a reappraisal. Gama R, Shah S, Wright J, Marks V, Diabet Med 1995 12 321 324 10.1111/j.1464-5491.1995. tb00485.x 7600747
25. Postprandial lipid metabolism and B-cell function in non-insulin- dependent (type 2) diabetes mellitus after mixed meals with a high fat content. Cooper MB, Tan KCB, Hales CN, Diabetic Med 1996 13 816 827 10.1002/(SICI)1096- 9136(199609)13:9<816::AID-DIA183>3.0.CO;2-L 8891457 (Pubitemid 26316266)
26. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Del Prato S, Tiengo A, Diabetes Metab Res Rev 2001 17 164 174 10.1002/dmrr.198 11424229 (Pubitemid 32624599)
27. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Pfützner A, Pfützner AH, Larbig M, Forst T, Diabetes Technol Ther 2004 6 405 412 10.1089/152091504774198124 15198846 (Pubitemid 38821628)